References
1. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden.
Schizophr Res. 2000;29: 21-28.
2. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease.
Am Heart J. 2005;150: 1115-1121.
3. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia.
J Clin Psychiatry. 2003;64:575-579.
4. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
JAMA. 2002;288:2709-2716.
5. Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.
Schizophr Res. 2007;90:162-173.
6. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia.
Br J Psychiatry. 2000;177:212-217.
7. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia.
Psychiatr Serv. 2003; 54:565-567.
8. Fontaine KR, Bartlett SJ, Barofsky I. Health-related quality of life among obese persons seeking and not currently seeking treatment.
Int J Eat Disord. 2000;27:101-105.
9. Perkins DO. Adherence to antipsychotic medications.
J Clin Psychiatry. 1999;60(suppl 21):25-30.
10. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.
Can J Psychiatry. 2004;49:753-760.
11. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.
Clin Pract Epidemol Ment Health. 2006;27:14.
12. Fenton WS, Chavez MR. Medication-induced weight gain and dyslipidemia in patients with schizophrenia.
Am J Psychiatry. 2006;163: 1697-1704.
13. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Schizophr Res. 2005;80:19-32.
14. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
Schizophr Res. 2006; 86:15-22.
15. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history.
J Hypertens. 2006;24:621-626.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA. 2001;285:2486-2497.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
Diabet Med. 1998;15:539-553.
18. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Available at:
http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed January 7, 2008.
19. Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment.
J Psychosom Res. 2002; 53:925-933.
20. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
CNS Drugs. 2005;19(suppl 1):1-93.
21. Bray GA. Drug insight: appetite suppressants.
Nat Clin Pract Gastroenterol Hepatol. 2005;2:89-95.
22. Masand PS. Relative weight gain among antipsychotics.
J Clin Psychiatry. 1999;60:706-708.
23. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels.
J Clin Psychiatry. 2001;62(suppl 27):27-34.
24. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review.
Drug Saf. 2001;24:59-73.
25. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Eur J Pharmacol. 2001;425:197-201.
26. Masand PS, Gupta S. Long-term adverse effects of novel antipsychotics.
J Psychiatr Pract. 2000;6:299-309.
27. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association Conference on scientific issues related to definition.
Circulation. 2004;109:433-438.
28. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contribution of various receptors to antipsychotic-induced weight gain and diabetes mellitus.
Drug Metab Pharmacokinet. 2005;27:368-378.
29. Silvestre JS, Prous J. Research on adverse drug events, I: muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
Methods Find Exp Clin Pharmacol. 2005;27:289-304.
30. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake.
Pharmacol Biochem Behav. 2003;75:255-260.
31. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
J Clin Psychiatry. 2002;63:425-433.
32. Metzler W, Fücker K, Schwanebeck U, et al. Significance of triglycerides for other metabolic parameters in the familiar metabolic syndrome [in German].
Dtsch Med Wochenschr. 2003;128:1941-1946.
33. Walton C, Lees B, Crook D, et al. Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age.
Am J Med. 1995;99:459-464.
34. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes.
J Clin Psychiatry. 2004;65:267-272.
35. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications.
Can J Psychiatry. 2006;51:492-501.
36. Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists.
J Clin Psychopharmacol. 2004;24 (5 suppl 1):S1-S6.
37. Cuffel B, Martin J, Joyce AT, et al. Lipid and glucose monitoring during atypical antipsychotic treatment: effects of the 2004 ADA/APPA consensus statement. Poster presented at: 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto.
38. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics.
J Clin Psychiatry. 2007;68 (suppl 4):14-18.
39. Brar JS, Ganguli R, Pandina G, et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
J Clin Psychiatry. 2005;66:205-212.
40. Hanssens L, De Hert M, Kalnicka D, et al. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
Int Clin Psychopharmacol. 2007;22:43-49.
41. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychoctic therapy: the role of "switching" medications.
J Clin Psychiatry. 2007;68(suppl 6):14-23.
42. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of North American trials.
J Clin Psychiatry. 1997;58:538-546.
43. Zeldox (ziprasidone hydrochloride capsules) NDA 20-825 [briefing document Pfizer]. Presented at: the FDA Psychopharmacological Drugs Advisory Committee; July 2000.
44. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study.
Am J Psychiatry. 2000;157:975-981.
45. Taylor DM, McAskill R. Aypical antipsychotics and weight gain: a systematic review.
Acta Psychiatr Scand. 2000;101:416-432.
46. Jones AM, Rak IW, Raniwalla J, et al. Weight changes in patients treated with quetiapine. Presented at: 153rd Annual Meeting of the American Psychiatric Association; May 2000; Chicago. Abstract NR 712:250.
47. Bustillo JR, Buchanan RW, Irish D, Breier A, et al. Differential effect of clozapine on weight: a controlled study.
Am J Psychiatry. 1996;153: 817-819.
48. Nemeroff CB. Dosing the antipsychotic medication olanzapine.
J Clin Psychiatry. 1997;58(suppl 10):45-49.
49. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
J Clin Psychiatry. 2001;62:92-100.
50. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials.
J Psychopharmacol. 1997;11:65-71.
51. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities.
J Clin Psychiatry. 1999;60:358-363.
52. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis.
Am J Psychiatry. 1999;156: 1686-1696.
53. Csernansky J, Okamoto A. Risperidone versus haloperidol for prevention of relapse in schizophrenia. Presented at: 10th Annual Meeting of the Biennial Winter Workshop on Schizophrenia; February 2000; Davos, Switzerland.
54. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
N Engl J Med. 2002;346:16-22.
55. Jody D, Saha AR, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole.
Int J Neuropsychopharmacol. 2002;5:S186.
56. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
N Engl J Med. 2005;353:1209-1223.
57. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
J Clin Psychiatry. 2003;64:580-588.
58. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents.
Psychopharmacology (Berl). 2003;166:391-399.
59. Simpson GM, Weiden PJ, Loebel A, et al. Long-term improvements of symptoms in an extension study of ziprasidone. Presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York.
60. Baptista T, Hernàndez L, Prieto LA, et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study.
J Clin Psychiatry. 2001;62:653-655.
61. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs.
Am J Psychiatry. 2002;159:655-657.
62. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment.
Eur Neuropsychopharmacol. 2001;11: 181-182.
63. Gupta S, Masand PS, Frank BL, et al. Topiramate in bipolar and schizaffective disorders: weight loss and efficacy.
Prim Care Companion J Clin Psychiatry. 2000;2:96-100.
64. Sacchetti E, Guarneri L, Bravi D. H
2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.
Biol Psychiatry. 2000;48:167-168.
65. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Int Clin Psychopharmacol. 2002;17:145-60.
66. Weiden PJ, Loebel A, Yang R, et al. Course of weight and metabolic effects 1 year after switching to ziprasidone. Presented at: 157th Annual Meeting of the American Psychiatric Association; May 2004; New York.
67. Litman R, Maiorca M, Courage E, et al. Body mass indices, lipid and glucose metabolism in olanzapine-treated schizophrenia patients before and after switching to aripiprazole. Presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 2003; San Juan, Puerto Rico.
68. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels.
J Clin Psychiatry. 2002;63:856-865.
69. Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride.
Curr Med Res Opin. 2002;18:201-208.
70. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching between second-generation antipsychotics: why and how?
CNS Drugs. 2005;19:27-42.
71. Citrome L. The effectiveness criterion: balancing efficacy against the risks of weight gain.
J Clin Psychiatry. 2007;68(suppl 12):12-17.
72. Correll CU. Real-life switching strategies with second-generation antipsychotics.
J Clin Psychiatry. 2006;67:160-161.
73. American Diabetes Association. Standards of medical care in diabetes.
Diabetes Care. 2005;28:S4-S36.
